Igenica Raises $24M in Series B to Expand Antibody Platforms

Hollingsworth, Catherine
June 2010
BioWorld Today;6/11/2010, Vol. 21 Issue 112, p1
The article reports on the completion of the 24 million U.S. dollar Series B financing of Igenica Inc., a pharmaceutical biotechnology firm based in Burlingame, California. The financing would enable Igenica to accelerate its efforts discover and develop cancer medicines based on antibodies. Proceeds from the financing would be used to expand the sTAg platform, a proteomics-based technology of Igenica, according to Chief Executive Officer (CE) Mike Rothe.


Related Articles

  • Molecular Partners Gets $15M For DARPin Proteins.  // Bioworld Week;8/20/2007, Vol. 15 Issue 34, p4 

    The article reports that Molecular Partners AG has raised $15.3 million in a Series A round to advance its preclinical portfolio of Designed Ankyrin Repeat Proteins (DARPin), which have multiple therapeutic and diagnostic applications. Molecular Partners chief executive officer (CEO) Christian...

  • FURTHER READING.  // PharmaWatch: Cancer;Feb2008, Vol. 7 Issue 2, p22 

    A list of articles related to cancer therapies is presented.

  • In 2003, CEOs must win confidence game. Reed, Robert // Crain's Chicago Business;12/23/2002, Vol. 25 Issue 51, p8 

    Focuses on the need to maintain the corporate credibility by the chief executive officers (CEOs) in the year 2003. Survey to determine the confidence of people in CEOs; Trustworthiness of people in Dow Jones Industrial companies; Confidence level of customers in finances of company.

  • Bill Conn. Thomson, James // BRW;9/6/2001, Vol. 23 Issue 35, p26 

    Profiles Bill Conn, an Australian Chief Executive Officer at Potter Partners Co. Career background; Views on corporate finance; Achievements.

  • It's the borrower, stupid... Posner, Bruce G. // Inc.;Jan94, Vol. 16 Issue 1, p102 

    Provides information from Coopers & Lybrand's `Trendsetter Barometer,' September 1993, which surveyed nearly 400 CEOs of growing businesses on their role in financing travails. What the CEOs cited as the main reasons they have trouble with banks.

  • P/C Executives: Focus on Infrastructure Updates. Buck, Michael // Best's Review;Feb2015, Vol. 115 Issue 10, p78 

    The article presents the remarks of industry executives on the intent of numerous chief executive officers (CEO) to focus on consumer and capital expenditure infrastructures to boost their businesses' images.

  • What Happens When an Interim CEO Takes Over? Frick, Walter // Harvard Business Review Digital Articles;6/12/2015, p2 

    The article discusses the findings of a study conducted by researchers from the University of Virginia which examined how the appointment of an interim chief executive officer affects the company's financial performance.

  • Foiling counterfeiters with nanotechnology. Colias, Mike // Crain's Chicago Business;3/10/2008, Vol. 31 Issue 10, p6 

    The article profiles James M. Hussey, chief executive officer (CEO) of NanoInk Inc. He got his bachelor's degree in pharmacy from Butler University, Indianapolis, in 1982. His first job was to accelerate sales of NanoInk's first product, Nanoencryption, which encodes pills and capsules with an...

  • John Oyler Aims To Build China's Genentech via Beigene. Yoffee, Lynn // BioWorld Today;11/22/2013, Vol. 24 Issue 226, p1 

    The article focuses on John Oyler, chief executive officer and co-founder of therapeutics firm Beigene Co. Ltd. Oyler's rising status as a sought-after speaker at international biopharmaceutical conferences is highlighted. He co-founded Beigene in 2010 with Xiaodong Wang who is also the director...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics